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Highly active antiretroviral therapy (HAART)
has become the standard for treating HIV infec-
tion.[1] HIV protease inhibitors (PIs) have been
used as amajor component of theHAART regimens
over the past 10 years, along with nucleoside and
non-nucleoside reverse transcriptase inhibitors.
The introduction of these regimens resulted in an
appreciable decline in morbidity and mortality
due to HIV infection.[2,3]
Tipranavir (TPV) is a nonpeptidic PI, approved
by the US FDA and the European Medicines
Agency for the treatment of HIV infection. The
structure of this molecule is a sulfonamide-
substituted dihydropyrone. Similar to other PIs,
TPV binds directly to HIV aspartyl protease, dis-
rupting the catalytic site of the enzyme and pre-
venting protease-dependent cleavage of HIV gag
and gag-pol polyproteins into smaller functional
proteins.[4-6] For this reason, the chance to develop
resistance is not so easy. TPV is active against
PI multidrug resistant viruses and it has been
very difficult to corner HIV to mutate through
subsequent in vitro passages.[7-9] TPV plus low-
dose ritonavir (TPV/r) is used in combination
with other antiretroviral (ARV) drugs. The advan-
tages of this approach include raising trough drug
concentrations, minimizing inter-patient variability,
prolonging drug elimination half-life, and reduc-
ing pill burden.[10,11] Results in the efficacy of the
selected dose of TPV/r (500/200mg twice daily)
were quite encouraging in extensively treated HIV-
infected patients. TPV is generallywell tolerated; the
most frequent adverse events were in the gastro-
intestinal system and laboratory abnormalities, such
as alteration of the lipid profile and liver function.[12]
Darunavir (DRV) is another new-generation
nonpeptidic HIV protease inhibitor approved
by the FDA, used with low doses of ritonavir
(600/100mg twice daily) for pharmacologic en-
hancement (boosting). It has demonstrated potent
activity against multidrug-resistant HIV in heavily
treatment-experienced patients with HIV infection.
Like TPV, DRV needs multiple mutations in the
HIV protease for the virus to build a significant
resistance to these drugs. For this reason, TPV and
DRV exhibit a high genetic barrier to the emergence
of novel resistant strains.[13,14] Boosted DRV is
generally well tolerated, with a lower incidence of
diarrhea and modification of the lipid profile.[15]
The aim of the POTENT trial[16] was the head-
to-head comparison of the safety and efficacy of
TPV versus DRV plus a low dose of ritonavir,
eachwith an optimized background regimen (OBR)
in triple-class-experienced HIV-infected patients,
being resistant to more than one PI.
This study was designed in 2007 (20 September)
to enroll and treat 800 HIV-1-positive patients,
randomly assigned (1 : 1) to one of the two
arms: TPV/r (500/200mg twice daily) or DRV/r
(600/100mg twice daily), with a treatment period
of 50 weeks. Both drugs were administered in
combination with another selected ARV, based
on patient therapeutic history (and virtual pheno-
type screening results).
The major shortcoming of the POTENT trial
was the very low enrollment numbers: only 39 pa-
tients (5% of the planned number) were random-
ized and received drugs prior to early termination
of the study (1 July 2008). The data from the trial,
due to poor patient enrollment and premature
termination, are insufficient to assess primary
and secondary previously established endpoints.
For this reason, statistical tests were not applied
to this collected observational data.
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The demonstrations of effect of TPV/r have
beenmore evident in treatment-experienced patients
with HIV infection receiving an OBR including
two fully active drugs. The use of enfuvirtide for
the first time has been correlated with a higher rate
of virologic success when combined with TPV/r.[12]
TPV/r is generally well tolerated, nevertheless
clinical hepatitis and hepatic decompensation
have been associated with its use. Although ini-
tially reported, a recent case review from the FDA
did not identify new safety concerns regarding
intracranial hemorrhage. Hepatic evaluation is
highly recommended in co-infected patients who
are at risk for hepatic decompensation.[17,18]
There is evidence that mutations conferring
resistance to TPV are not related to resistance to
DRV. This may be important for the potential
sequencing of these two PI in multiple ARV-
experienced patients. A substantial susceptibility
to TPV and DRV of viral isolates derived from
patients with a massive ARV drug experience has
been reported.[19] In multiple ARV-experienced
patients with resistance to one or more PI, TPV
and DRV remain the most likely active PIs for
constructing an effective drug regimen.
Nowadays, mostly achievable goals of ARV
are to further reduce HIV-related morbidity and
mortality, improve quality of life, and restore and
preserve immunologic function in HIV-infected
individuals through a sustained suppression of
HIV replication.[20,21]
It is not so easy to design a trial such as
POTENT where even after significant efforts to
enroll patients, the number of individuals in-
cluded in the study and time in the follow-up were
insufficient to draw definitive conclusions. Fur-
thermore, the POTENT trial included a com-
parison between two PIs; however what we really
need are combination regimens including drugs
with new mechanisms of action, new cellular
targets and novel chemical structures (e.g. co-
receptor or integrase inhibitors), together with an
improved tolerability profile.[22]
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